In this study, we found that in comparison with that in the placebo group, XZP treatment significantly mitigated the bone cancer-upregulated RANKL, RANK, PTHrP, IGF-1, IL-8, M-CSF, and TNF-α but increased the levels of OPG expression in the tibial bones of rats, accompanied by decreased numbers of osteoclasts and osteoblasts. The gene discussed is TNFRSF11B; the disease is bone cancer.